Precigen Corp (PGEN) - Long-Term Debt to Capital Coefficient

The current price chart for Precigen, Inc. (PGEN) serves as an indicator for a business developing gene therapy via the UltraVector system, where success depends on FDA approval of PRGN-2012 and expense control. The company is currently transitioning to the commercial launch of treatments for rare respiratory pathologies, with the metric standing at 2.39. The growth model relies on the high margins of proprietary drugs offsetting initial R&D costs.

This ratio assesses the company's dependence on long-term liabilities relative to equity, allowing for the identification of excessive leverage risks should borrowing costs fluctuate. The current value of 2.39 and the long-term debt-to-equity trend reflect the financial stability of Precigen, Inc., whose strategy of outsourcing production and testing to external partners minimizes capital expenditures, thereby reducing the need for massive debt financing.